Randomized Comparison of Continuous and Intermittent Heparin Infusion During Catheter Ablation of Atrial Fibrillation
Information source: Seoul St. Mary's Hospital
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Coagulation; Intravascular
Intervention: Continuous heparin infusion (Drug); Intermittent heparin infusion (Drug)
Phase: Phase 3
Status: Recruiting
Sponsored by: Seoul St. Mary's Hospital Official(s) and/or principal investigator(s): Yong Seog Oh, MD, Principal Investigator, Affiliation: Seoul St. Mary's Hospital
Overall contact: Yong Seog Oh, MD, Phone: 82-2-2258-1141, Email: oys@catholic.ac.kr
Summary
Optimal anticoagulation using heparin with close attention to maintain therapeutic dosing
during the procedure is important.
Randomized comparison of continuous and intermittent heparin infusion during catheter
ablation of Atrial Fibrillation.
Clinical Details
Official title: Randomized Comparison of Continuous and Intermittent Heparin Infusion During Catheter Ablation of Atrial Fibrillation
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Primary outcome: therapeutic ACT retention rate during procedure
Detailed description:
Intravenous heparin was used during the procedure to prevent catheter-induced thrombosis.
heparin is administered during the procedure to achieve recommended activation clotting
times (ACT) values, typically >300 seconds to prevent thromboemboli during the procedure.
Most of the practitioners was that ACT level should be checked at 30- to 60-minute intervals
and then have injected intermittently.
intermittent heparin infusion, concentration is great changed because the heparin has
30minutes half-period.
researchers postulate that a constant therapeutic concentrations would be beneficial to
continuous infusion than intermittent infusion.
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Atrial Fibrillation, Radiofrequency catheter ablation scheduled
Exclusion Criteria:
- Clinical trial denied
Locations and Contacts
Yong Seog Oh, MD, Phone: 82-2-2258-1141, Email: oys@catholic.ac.kr
Seoul st. mary's hospital, Seoul, Korea, Republic of; Recruiting
Additional Information
Starting date: December 2012
Last updated: May 23, 2015
|